Key result
Chemiluminescence immunoassay and LC-MS/MS exhibited comparable diagnostic efficacy in screening for primary aldosteronism (AUC 0.968 vs 0.950, P=0.249).
Why the study?
Whether CLIA and LC-MS/MS for plasma aldosterone concentration measurement can be used interchangeably in primary aldosteronism screening remains controversial.
Does chemiluminescence immunoassay provide comparable diagnostic efficacy to liquid chromatography-tandem mass spectrometry for measuring plasma aldosterone in primary aldosteronism screening?
Cross-Sectional (n=125)
Does chemiluminescence immunoassay provide comparable diagnostic efficacy to liquid chromatography-tandem mass spectrometry for measuring plasma aldosterone in primary aldosteronism screening?
Absolute Event Rate: 0.968% vs 0.95%
p-value: p=0.249
CLIA is a reliable and feasible alternative to LC-MS/MS for plasma aldosterone measurement in primary aldosteronism screening, despite yielding higher absolute values.
Supports CLIA as feasible alternative for PA screening; leaves open need for method-specific validation before broader adoption.
Whether chemiluminescence immunoassay (CLIA) and liquid chromatography-tandem mass spectrometry (LC-MS/MS) for plasma aldosterone concentration (PAC) measurement can be used interchangeably in primary aldosteronism (PA) screening is still controversial. The purpose of this study was to compare CLIA to LC-MS/MS for PAC measurement in PA screening. All participants underwent aldosterone-to-renin ratio (ARR) testing. PA was diagnosed by captopril challenge test or saline infusion test. PAC in screening test was measured with CLIA and LC-MS/MS. Plasma direct renin concentration in screening and confirmatory test was measured with CLIA. The concordance between CLIA and LC-MS/MS for PAC measurement in PA screening was analyzed. Twenty-one healthy volunteers, 61 patients with essential hypertension (EH) and 43 PA patients were enrolled. Median PAC by CLIA was 84.7 % higher than that by LC-MS/MS in screening test (P < 0.001). A positive correlation of PAC was observed between the two assays (Pearson r coefficient 0.770, P < 0.001). When ARR was used in differentiating PA from EH, there was no difference in the area under the receiver operating characteristic curve between CLIA and LC-MS/MS for PAC measurement (0.968 vs 0.950, P = 0.249). CLIA and LC-MS/MS for PAC measurement exhibited high and comparable efficacy in PA screening. CLIA is a reliable and feasible alternative in PA screening test.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2024) conducted a cross-sectional in Primary aldosteronism (n=125). Chemiluminescence immunoassay (CLIA) vs. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) was evaluated on Area under the receiver operating characteristic curve (AUC) for differentiating primary aldosteronism from essential hypertension (p=0.249). Chemiluminescence immunoassay and LC-MS/MS exhibited comparable diagnostic efficacy in screening for primary aldosteronism (AUC 0.968 vs 0.950, P=0.249).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: